Lightpoint Medical, a company based in Rickmansworth, England, obtained European approval to launch the LightPath Imaging System. The device allows clinicians to intraoperatively review excised tissue for signs of cancer, increasing confidence that the whole tumor has been removed and not relying on a pathologist to do the analysis. It is the first such approved system in the world to do intraoperative molecular imaging for cancerous tissue detection.
The system performs Cherenkov luminescence imaging, looking for light arising from PET contrast agents within the tissue.
It is currently being made available in European markets with a rollout in the U.S. scheduled for next year.
Here are the tech specs according to the product page:
- High spatial resolution: 117 μm intrinsic resolution.
- Wide field-of-view: 6×6 cm2 FOV.
- High sensitivity: 1.1 × 105photons/sec/cm2/sr/(kBq/μl) for Fluorine-18.
- High performance optics: f/0.95 lens and thermoelectrically-cooled emCCD.
- Spectral selectivity: 5-wavelength filter-wheel.
Product page: LightPath…
Source: Lightpoint Medical…